You are here: Industry Insights > lung cancer

News List

AstraZeneca’s immunotherapy fails in key lung cancer trial pharmaphorum
November 27, 2018
AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck & Co is enjoying huge sales success with Keytruda.
AstraZeneca sharpens Imfinzi's lung cancer edge with big survival win fiercepharma
September 28, 2018
AstraZeneca already has an OK to market Imfinzi for stage 3 lung cancer that can't be surgically removed. But just-unveiled survival data will strengthen its case—and its lead over its immuno-oncology rivals
AZ’s immunotherapy combo fails again in lung cancer pharmaphorum
April 26, 2018
AstraZeneca had placed its immunotherapy Imfinzi (durvalumab) at the centre of its efforts to rebuild its sales – but after a shock failure last year in first line lung cancer, the drug has also come up short in previously treated patients.
AZ lung cancer combo fails to hit targets pharmatimes
April 25, 2018
A combination of immunotherapy drugs being tested by AstraZeneca in the third-line setting in patients with lung cancer has failed to slow disease progression or extend survival.
US widens use of AZ’ Tagrisso in lung cancer pharmatimes
April 23, 2018
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
New immunotherapy for lung cancer shows promise of success worldpharmanews
April 11, 2018
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression
Merck’s Keytruda Grabs Another Late-Stage Clinical Win in Lung Cancer biospace
April 10, 2018
Merck & Co. is chalking up another clinical win for its potent checkpoint inhibitor Keytruda.
Genentech's Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients Live Longer Genentech's Late-Stage Trial Data Shows Combinatio
March 27, 2018
Genentech plans to seek regulatory approval for compliance with lung cancer treatment because...
Genentech's Tecentriq Shows Promise for First-line Lung Cancer Treatment biospace
March 21, 2018
Genentech, Inc., a Roche Group company, indicated its IMpower131 Phase III clinical trial of Tecentriq with carboplatin and Abraxane met its co-primary endpoint of progression-free survival (PFS) in lung cancer
Merrimack Pharmaceuticals Expands Phase II Lung Cancer Study biospace
March 13, 2018
Merrimack Pharmaceuticals Inc. saw a slight uptick in pre-market trading this morning after the company announced it is expanding enrollment in a Phase II lung cancer study.

Previous page 1 2 Next page